Metabolic · 1 min read
Semaglutide vs Tirzepatide vs Retatrutide: One, Two, Three Receptors
Single, dual and triple receptor targets, the key trials behind each, and the limits of comparing separate studies.
By the Compound Lab editorial teamPublished
Receptor targets
Incretin research has moved from single-receptor agonism to multi-receptor designs that aim to combine complementary metabolic effects.
Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts on both GIP and GLP-1 receptors. Retatrutide adds the glucagon receptor, making it a triple agonist.
The key trials
Semaglutide's weight-management programme is anchored by the STEP trials, tirzepatide's by SURMOUNT, and retatrutide's published evidence by a phase 2 trial in adults with obesity.
Each programme enrolled different populations over different durations, which matters when reading any comparison table.
Comparing trials
Populations, durations and endpoints differ between trials, so placing results side by side from separate studies is an indirect comparison.
Head-to-head data are the most reliable basis for ranking compounds. SURMOUNT-5 compared tirzepatide directly with semaglutide; for retatrutide, rely on the original trial reports rather than cross-trial league tables.
Continue with
Sources and evidence
- 01Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (opens in a new tab)N Engl J Med 2021
- 02Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (opens in a new tab)N Engl J Med 2022
- 03Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (opens in a new tab)N Engl J Med 2023
- 04Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) (opens in a new tab)N Engl J Med 2025
Sources compiled for this concept; Compound Lab's editorial team should review them before launch.
For laboratory research reference only. This article is not medical advice.